Atlas Trials

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Clinical trial NCT04176393 · COMPLETED

Trial details

NCT number
NCT04176393
Sponsor
CStone Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Acute Myeloid Leukemia
Start date
2019-11-12
Primary completion
2021-02-18
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.